Drug developers Aspen Neuroscience and Bambusa Therapeutics launched their US initial public offering roadshows on Monday, adding to a wave of issuers from the biotech industry that have tapped the fall IPO window.
Drugmakers were expecting big things when generic Ozempic hit Indian pharmacies. But it didn’t happen.
In March, Indian patents on the active ingredient in weight-loss drugs Ozempic and Wegovy expired, unleashing a flood of cheaper copycat versions in the country. The medical community is now realizing that cost is just one of many barriers, particularly in India, to the adoption of weight-loss medications. Read the full Businessweek story here:
🎨: Hitesh Sonar for Bloomberg Businessweek; 📷️: Getty Images (2)
Drug discovery is becoming a computational science. Richard Bonneau leads AI for drug discovery at @Genentech.
Catch him bringing what's actually working to #FullyConnected26#. Sept 29–Oct 1, SF.
Register here:
Drugmakers found a promising cure for the obesity epidemic and their stocks were rewarded for it. Now, investors are salivating over a new crop of companies tackling a more purely aesthetic problem: baldness. Read more:
📷️: Gabby Jones/Bloomberg